← Back to Search

Anti-arrhythmic drug

Cryoballoon-based PVI for Atrial Fibrillation (PROGRESSIVE-AF Trial)

N/A
Waitlist Available
Led By Jason Andrade
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 12, 24, and 36 months following treatment initiation
Awards & highlights

PROGRESSIVE-AF Trial Summary

This trial is studying whether a treatment to prevent atrial fibrillation (AF) is more effective when given early on, before the disease has progressed. The study will compare two treatments: catheter-based pulmonary vein isolation (PVI) using cryothermal energy, and anti-arrhythmic drug therapy. The aim is to see if the initial treatment choice influences AF disease progression, as measured by continuous cardiac monitoring.

PROGRESSIVE-AF Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 12, 24, and 36 months following treatment initiation
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 12, 24, and 36 months following treatment initiation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Time to First Occurrence of Persistent Atrial Tachyarrhythmia
Secondary outcome measures
Atrial Fibrillation Burden
Health Related Quality of Life
Healthcare utilisation
+3 more

PROGRESSIVE-AF Trial Design

2Treatment groups
Active Control
Group I: Cryoballoon-based PVIActive Control1 Intervention
Sinus rhythm control via a pulmonary vein isolation (PVI) ("first-line") procedure utilizing the the Arctic Front Cryoballoon Procedure.
Group II: Anti-Arrhythmic Drug TherapyActive Control1 Intervention
Sinus rhythm control via the use of anti-arrhythmic drug (AAD) therapy ("first-line") based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF.

Find a Location

Who is running the clinical trial?

University of British ColumbiaLead Sponsor
1,418 Previous Clinical Trials
2,466,815 Total Patients Enrolled
9 Trials studying Atrial Fibrillation
1,521 Patients Enrolled for Atrial Fibrillation
Ottawa Heart Institute Research CorporationOTHER
188 Previous Clinical Trials
92,133 Total Patients Enrolled
23 Trials studying Atrial Fibrillation
6,388 Patients Enrolled for Atrial Fibrillation
MedtronicIndustry Sponsor
606 Previous Clinical Trials
828,362 Total Patients Enrolled
64 Trials studying Atrial Fibrillation
18,968 Patients Enrolled for Atrial Fibrillation

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
The Impact of "First-Line" Rhythm Therapy on AF Progression
Jason Andrade 2017. "The Impact of "First-Line" Rhythm Therapy on AF Progression". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05514860.
~37 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top